Mauna Kea Technologies Revenue and Competitors

Allston,

Location

$60.5M

Total Funding

Estimated Revenue & Valuation

  • Mauna Kea Technologies's estimated annual revenue is currently $55.5M per year.(i)
  • Mauna Kea Technologies's estimated revenue per employee is $313,750
  • Mauna Kea Technologies's total funding is $60.5M.

Employee Data

  • Mauna Kea Technologies has 177 Employees.(i)
  • Mauna Kea Technologies grew their employee count by -1% last year.

Mauna Kea Technologies's People

NameTitleEmail/Phone
1
Chief Scientific OfficerReveal Email/Phone
2
VP, Global Marketing & U.S. SalesReveal Email/Phone
3
Director Clinical and Regulatory AffairsReveal Email/Phone
4
Human Resources DirectorReveal Email/Phone
5
Chief Innovation OfficerReveal Email/Phone
6
Director Sales, USReveal Email/Phone
7
Chief Technology OfficerReveal Email/Phone
8
Chief Operating OfficerReveal Email/Phone
9
Director Sales, USReveal Email/Phone
10
Strategic Partnership Program ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$6.1M49-18%$10MN/A
#2
$30.4M12129%N/AN/A
#3
$139.8M913-3%$200KN/A
#4
$84.1M0N/A$1.2MN/A
#5
$43.4M17330%N/AN/A
#6
$64.5M25712%N/AN/A
#7
$64.3M20526%$129.6MN/A
#8
$19.6M78-7%N/AN/A
#9
$65.8M2627%N/AN/A
#10
$73.7M23520%$115.5MN/A
Add Company

What Is Mauna Kea Technologies?

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Companyᅢᄁ¬ツᆲ¬トᄁs flagship product, Cellvizio, has received clearance/approval in a wide range of applications in more than 40 countries, including the United States, Europe, Japan, and China.

keywords:N/A

$60.5M

Total Funding

177

Number of Employees

$55.5M

Revenue (est)

-1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Mauna Kea Technologies News

2022-04-20 - Minimally Invasive Biopsy Technologies Market Size And Analysis ...

Top Companies Covered In This Report: Chronix Biomedical, Biocept, Inc., F. Hoffmann-La Roche Ltd, Mauna Kea Technologies, Veracyte, Inc.,...

2022-04-19 - Mauna Kea Technologies Publishes Q1 2022 Sales and Its 2021 ...

Mauna Kea Technologies (Euronext: MKEA) (Paris:MKEA) (OTCQX:MKEAY), inventor of Cellvizio®, the multidisciplinary probe and needle confocal...

2022-04-13 - Mauna Kea Technologies Announces First of Its Kind U.S. FDA 510 ...

Mauna Kea Technologies (Euronext: MKEA, 'Mauna Kea') inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser...

2021-10-04 - Mauna Kea Technologies : Announces 5 Communications Highlighting the Clinical Value of Cellvizio® in Interventional Pulmonology Presented During the ERS International Congress 2021

Mauna Kea Technologies Announces 5 Communications Highlighting the Clinical Value of Cellvizio® in Interventional Pulmonology Presented During the European Respiratory Society (ERS) International Congress 2021 Further validation of how Cellvizio is a complementary technology to manual and rob ...

2021-04-22 - MAUNA KEA TECHNOLOGIES Mauna Kea Technologies : sets up an equity financing facility with Kepler Cheuvreux

Mauna Kea Technologies sets up an equity financing facility with Kepler Cheuvreux Paris and Boston, April 22, 2021 - 5:45 PM CEST - Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-basedconfocal laser endomicroscopy (p/nCLE) platform, annou ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$47.8M212-2%N/A
#2
$71M23915%N/A
#3
$157.2M3816%N/A